Call for Abstracts

EACR 2025 Congress

Abstract submission deadline: **06 March 2025**

Abstracts can only be submitted online.

Abstract Regulations

With the submission of an abstract to the EACR 2025 Congress, the submitting author/presenting author:

- Accepts responsibility for the accuracy of the submitted abstract.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been published **in the same format** and **with the same title** prior to the date of the Congress.
- Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
- States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
- Gives permission for the abstract, when selected for presentation (oral or poster), to be published in an online supplement to the journal *Molecular Oncology*, and by the EACR on the Congress website and through the Congress app.

Presentation of abstracts: All abstracts selected for oral or poster presentation at the EACR Annual Congress 2025 must be presented in person.

The submitting author for each abstract must designate a presenter who agrees to register for the Congress and present in detail the research discussed in the abstract. **We strongly advise that presenting authors put funding and/or visa arrangements in place as early as possible to avoid disappointment.**

If the assigned presenter cannot attend the Congress, the authors are expected to designate a replacement or withdraw the abstract no later than 28 April 2025.

If by 28 April 2025 the presenting author of the abstract is not registered the abstract will be withdrawn from the programme and publication.

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

- The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts which are presented in poor English, or may request an immediate revision by the presenter.
- Abstract titles should be brief and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- **No more than 10 authors can be listed.** Only institutional affiliations, cities and countries should follow.

- Abstracts should be organised under the headings:

    - Introduction
    - Material and method
    - Results and discussion
    - Conclusion

- The online abstract submission procedure will **not** accept abstracts that exceed 2,500 characters (body of the abstract; without spaces)
- Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower case. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. "generic (Commercial ®)".
- Supplementary data or appendices will not be accepted.
- Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be included in the text itself.

Only the **submitting author** will receive a confirmation/abstract number by email from the EACR 2025 Congress Team within 48 hours of submission. This confirmation of abstract receipt is **NOT** a notice of acceptance to present at the Congress.

We strongly advise that presenting authors put funding and/or visa arrangements in place as early as possible after submission to avoid disappointment.

For questions regarding the online submission process, please contact our support team via: eacr@newway-management.com

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for oral and poster presentations by **08 April 2025**. The presenting author will receive an email with the result of the review and the Scientific Committee's decision on the abstract no later than **08 April 2025**. Depending on the selection of presentation format by the committee, further instructions on how to prepare posters or presentations at the Congress will be provided. If a selected author cannot present, the presenting author should assign a replacement presenter to present the abstract.

The following presentation formats are applicable for the EACR 2025 Congress:

1. **Oral presentation:** the abstract is selected for oral presentation in a main Congress symposium
2. **Poster:** abstracts that have been selected for presentation in a poster format. Posters are grouped by (main) topic and displayed during specific Poster Sessions.
   A formal Poster Defence Session will be scheduled.
3. **Poster Presentation with Poster in the Spotlight session:** in addition to a poster presentation as above, **a 5-minute presentation** is delivered at a designated time **in the Posters in the Spotlight Session**, located in the poster and exhibition area.

Please note that if your abstract is accepted for oral or poster presentation, the abstract will only be published in the Congress abstract publications **if the presenting author has registered and paid for the Congress by 28 April 2025**.

If the presenting author has not registered and paid by 28 April 2025, the abstract will not be published or accessible in the Congress Abstract Publications, and a poster board will not be provided.

Only abstracts submitted online will be accepted. Abstracts submitted on paper or as email attachment will not be considered**.**

There is no Late Breaking Abstract submission for the EACR 2025 Congress.

For questions regarding the online submission process, please contact: eacr@newway-management.com

Topics for Abstract Submission

1. **CANCER CELL BIOLOGY**
   - Cell Proliferation/Cell Cycle
   - Cell Death / Autophagy
   - Oncogenes and Tumour Suppressor Genes
   - Metastases and EMT
   - Aging and Cancer
   - Senescence
   - Cancer Cell Metabolism
   - Cancer Initiating Cells / Cancer Stem Cells

2. **CANCER GENOMICS**
   - Genomic Alterations in Cancer
   - Functional Genomics
   - Genomic profiling of Tumours
   - Large-scale Approaches to Cancer Gene Discovery
   - Spatial and 3D Analysis of Tumours
   - Genomes and Transcriptomes of Cancer at Single Cell Level

3. **EPIGENETICS**
   - DNA Methylation
   - Epigenetic changes as Molecular Markers of Cancer
   - Epigenomics
   - Histone Modification
   - Epigenetic Mechanisms and Gene Silencing
   - Chromatin Structure and Function

4. **BIOINFORMATICS AND COMPUTATIONAL BIOLOGY**
   - Application of Bioinformatics to Cancer Biology
   - Artificial Intelligence and Machine Learning
   - New Algorithms and new Software for Data Analysis
   - Mathematical Modeling and Statistical Methods
   - Molecular Modeling
   - Database Resources and Network Biology
   - Omics Technologies
   - Digital Clinical Trials

5. **TUMOUR EVOLUTION AND HETEROGENEITY**
   - Causes and Consequences of Tumour Heterogeneity
   - Methods to measure Tumour Evolution and Heterogeneity
   - Drug Resistance and Clonal Evolution

6. DRUG RESISTANCE

Novel Mechanisms
Regulation of Gene Expression in Drug Resistance
Reversal of Drug Resistance
Drug Transport and Metabolism
Resistance to Immune Checkpoint Blockade and other Immune based Therapies

7. BIOMARKERS IN TISSUE AND BLOOD

Liquid Biopsies: Circulating DNA
Liquid Biopsies: Circulating TumourCells
Diagnostic Biomarkers
Prognostic Biomarkers
Biomarkers Predictive of Therapeutic Benefit
Early Detection Biomarkers

8. SIGNALING PATHWAYS

Receptors and Signal Transduction
Gene Expression, Transcriptional Regulation
Systems Biology
Intracellular Networks
Computational Models of Biological Systems

9. CARCINOGENESIS

Mutagenesis, Carcinogen Metabolism
Promotion and Progression
DNA Damage and Repair
Viral Oncogenesis

10. TRANSLATIONAL RESEARCH

Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment
Molecular Pathology
Imaging
Clinical Phase I/II trials with Targeted Drugs and Novel Agents
Bioinformatics in Therapies and Clinical Trials
Infrastructures (Biobanks, Databases, Genomic Resources, others)
Nanotechnologies in Cancer Research

11. EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS

Drug Discovery / Drug Design
Novel Targets, Delivery Systems
Mechanisms of Drug Action, Drug Profiling
New Therapies
Pharmacogenetics and Therapeutic Response
Pharmacogenomics
Pharmacokinetics
Precision Medicine
Target Degradation

12. TUMOUR IMMUNOLOGY

Tumour Immunology
Immune Suppression and Escape
Tumour Antigens and Immune Effectors
Oncogenic Pathway-mediated Deregulation of Tumour Immunity
Antigen Processing and Presentation
Microbiome and Cancer

13. IMMUNOTHERAPY

Adoptive Cell Therapy
Immune Response to Therapies
Immunomodulatory Agents and Interventions
Therapeutic Antibodies, including Engineered Antibodies
Vaccines
Immune Checkpoints
Immune Mechanisms invoked by other Therapies including CARs

14. RADIOBIOLOGY / RADIATION ONCOLOGY

Tumour Cell Sensitisation to Radiotherapy
Radiation-activated Signaling Pathways
Cell Cycle and Apoptosis in Radiation Responses
Radiation Oncology; Preclinical and Clinical
Translational Radiation Research

15. MOLECULAR AND GENETIC EPIDEMIOLOGY

Risk Factors
Risk Assessment
Susceptibility Genes
Genotype / Phenotype Correlations
Genetic Polymorphisms and Cancer Susceptibility
Epidemiology

16. PREVENTION and EARLY DETECTION

Preclinical Prevention Studies, Markers and Prevention
Clinical Prevention Studies
Vaccination Against Cancer
Risk Factors: Heritable and Lifestyle related Risk Factors

17. TUMOUR BIOLOGY

Animal Models of Cancer
Genetic and Genomic Instability
Tumour Progression: Invasion and Metastasis
Tumour Microenvironment
Tumour Angiogenesis
Tumour Inflammation
RNA Biology in Cancer (splicing, noncoding RNAs, RNA modifications) and Therapy Response
Cell Competition
Tumour Dormancy and Persister Cells